{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:03:11Z","timestamp":1781269391540,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"50","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA273081"],"award-info":[{"award-number":["R01CA273081"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Department of Health & Human Services | U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["U01FD007925"],"award-info":[{"award-number":["U01FD007925"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2025,12,23]]},"DOI":"10.1038\/s41388-025-03637-0","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T09:59:18Z","timestamp":1764064758000},"page":"4910-4915","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Beyond genomics: 3D microtumor assays for rapid, clinically relevant functional drug testing"],"prefix":"10.1038","volume":"44","author":[{"given":"Marina","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4453-3031","authenticated-orcid":false,"given":"Taranjit S.","family":"Gujral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"3637_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11523-021-00796-4","volume":"16","author":"L Cortesi","year":"2021","unstructured":"Cortesi L, Rugo H, Jackisch C. An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol. 2021;16:255\u201382. PUBMED.","journal-title":"Target Oncol"},{"key":"3637_CR2","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1158\/1078-0432.CCR-18-2275","volume":"25","author":"F Meric-Bernstam","year":"2019","unstructured":"Meric-Bernstam F, Johnson AM, Dumbrava EEI, Raghav K, Balaji K, Bhatt M, et al. Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer. Clin Cancer Res. 2019;25:2033\u201341.","journal-title":"Clin Cancer Res"},{"key":"3637_CR3","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1111\/cas.16165","volume":"115","author":"S Takamizawa","year":"2024","unstructured":"Takamizawa S, Koyama T, Sunami K, Sudo K, Hirata M, Kubo T, et al. Identification of barriers to implementation of precision oncology in patients with rare cancers. Cancer Sci. 2024;115:2023\u201335.","journal-title":"Cancer Sci"},{"key":"3637_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","volume":"40","author":"A Letai","year":"2022","unstructured":"Letai A, Bhola P, Welm AL. Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer cell. 2022;40:26\u201335.","journal-title":"Cancer cell"},{"key":"3637_CR5","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/nm.4389","volume":"23","author":"A Letai","year":"2017","unstructured":"Letai A. Functional precision cancer medicine\u2014moving beyond pure genomics. Nat Med. 2017;23:1028\u201335.","journal-title":"Nat Med"},{"key":"3637_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00528-7","volume":"8","author":"N Struyf","year":"2024","unstructured":"Struyf N, \u00d6sterroos A, Vesterlund M, Arnroth C, James T, Sunandar S, et al. Delineating functional and molecular impact of ex vivo sample handling in precision medicine. NPJ Precis Oncol. 2024;8:38.","journal-title":"NPJ Precis Oncol"},{"key":"3637_CR7","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","volume":"12","author":"D Malani","year":"2022","unstructured":"Malani D, Kumar A, Br\u00fcck O, Kontro M, Yadav B, Helles\u00f8y M, et al. Implementing a functional precision medicine tumor board for acute myeloid leukemia. Cancer Discov. 2022;12:388\u2013401.","journal-title":"Cancer Discov"},{"key":"3637_CR8","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/2159-8290.CD-21-0538","volume":"12","author":"C Kornauth","year":"2022","unstructured":"Kornauth C, Pemovska T, Vladimer GI, Bayer G, Bergmann M, Eder S, et al. Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders. Cancer Discov. 2022;12:372\u201387.","journal-title":"Cancer Discov"},{"key":"3637_CR9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1182\/blood.2024024968","volume":"145","author":"S Kyt\u00f6l\u00e4","year":"2025","unstructured":"Kyt\u00f6l\u00e4 S, V\u00e4nttinen I, Ruokoranta T, Partanen A, Holopainen A, Saad J, et al. Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial. Blood. 2025;145:409\u201321.","journal-title":"Blood"},{"key":"3637_CR10","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1182\/blood-2016-02-699363","volume":"130","author":"R Karjalainen","year":"2017","unstructured":"Karjalainen R, Pemovska T, Popa M, Liu M, Javarappa KK, Majumder MM, et al. JAK1\/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell\u2013induced protection of AML. Blood. 2017;130:789\u2013802.","journal-title":"Blood"},{"key":"3637_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41416-019-0495-5","volume":"121","author":"CR Ireson","year":"2019","unstructured":"Ireson CR, Alavijeh MS, Palmer AM, Fowler ER, Jones HJ. The role of mouse tumour models in the discovery and development of anticancer drugs. Br J Cancer. 2019;121:101\u20138.","journal-title":"Br J Cancer"},{"key":"3637_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nrclinonc.2011.34","volume":"8","author":"L Hutchinson","year":"2011","unstructured":"Hutchinson L, Kirk R. High drug attrition rates\u2014where are we going wrong?. Nat Rev Clin Oncol. 2011;8:189\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"3637_CR13","doi-asserted-by":"publisher","DOI":"10.4155\/fsoa-2017-0003","volume":"3","author":"TG Meijer","year":"2017","unstructured":"Meijer TG, Naipal KA, Jager A, van Gent DC. Ex vivo tumor culture systems for functional drug testing and therapy response prediction. Fut Sci OA. 2017;3:FSO190.","journal-title":"Fut Sci OA"},{"key":"3637_CR14","doi-asserted-by":"publisher","DOI":"10.34133\/bmef.0022","volume":"4","author":"YL Huang","year":"2023","unstructured":"Huang YL, Dickerson LK, Kenerson H, Jiang X, Pillarisetty V, Tian Q, et al. Organotypic models for functional drug testing of human cancers. BME Front. 2023;4:0022.","journal-title":"BME Front"},{"key":"3637_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.18632\/oncotarget.26585","volume":"10","author":"N Nishida-Aoki","year":"2019","unstructured":"Nishida-Aoki N, Gujral TS. Emerging approaches to study cell\u2013cell interactions in tumor microenvironment. Oncotarget. 2019;10:785.","journal-title":"Oncotarget"},{"key":"3637_CR16","doi-asserted-by":"publisher","first-page":"e1670019","DOI":"10.1080\/2162402X.2019.1670019","volume":"8","author":"R Sivakumar","year":"2019","unstructured":"Sivakumar R, Chan M, Shin JS, Nishida-Aoki N, Kenerson HL, Elemento O, et al. Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery. Oncoimmunology. 2019;8:e1670019.","journal-title":"Oncoimmunology"},{"key":"3637_CR17","doi-asserted-by":"crossref","unstructured":"Jagatia R, Doornebal EJ, Rastovic U, Harris N, Feyide M, Lyons AM et al. Patient-derived precision cut tissue slices from primary liver cancer as a potential platform for preclinical drug testing. EBioMedicine. 2023;97.","DOI":"10.1016\/j.ebiom.2023.104826"},{"key":"3637_CR18","doi-asserted-by":"publisher","unstructured":"Nishida-Aoki N, Bondesson AJ, Gujral TS. Measuring real-time drug response in organotypic tumortissue slices. J Vis Exp. 2020;e61036. https:\/\/doi.org\/10.3791\/61036.","DOI":"10.3791\/61036"},{"key":"3637_CR19","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1039\/D0LC00801J","volume":"21","author":"LF Horowitz","year":"2021","unstructured":"Horowitz LF, Rodriguez AD, Au-Yeung A, Bishop KW, Barner LA, Mishra G, et al. Microdissected \u201ccuboids\u201d for microfluidic drug testing of intact tissues. Lab Chip. 2021;21:122\u201342.","journal-title":"Lab Chip"},{"key":"3637_CR20","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s12276-024-01272-5","volume":"56","author":"L Thorel","year":"2024","unstructured":"Thorel L, Perr\u00e9ard M, Florent R, Divoux J, Coffy S, Vincent A, et al. Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology. Exp Mol Med. 2024;56:1531\u201351.","journal-title":"Exp Mol Med"},{"key":"3637_CR21","doi-asserted-by":"crossref","unstructured":"Horowitz LF, Rodriguez-Mias R, Zhu S, Gottshall NR, Stepanov I, Stiles C et al. Microdissected tumor cuboids: a microscale cancer model that retains a complex tumor microenvironment. BioRxiv 2024. https:\/\/www.biorxiv.org\/content\/10.1101\/2024.03.22.586189v2.","DOI":"10.1101\/2024.03.22.586189"},{"key":"3637_CR22","doi-asserted-by":"publisher","first-page":"107668","DOI":"10.1016\/j.pharmthera.2020.107668","volume":"218","author":"R Xu","year":"2021","unstructured":"Xu R, Zhou X, Wang S, Trinkle C. Tumor organoid models in precision medicine and investigating cancer-stromal interactions. Pharmacol Therapeutics. 2021;218:107668.","journal-title":"Pharmacol Therapeutics"},{"key":"3637_CR23","doi-asserted-by":"publisher","first-page":"8352","DOI":"10.1073\/pnas.0907676107","volume":"107","author":"V Vaira","year":"2010","unstructured":"Vaira V, Fedele G, Pyne S, Fasoli E, Zadra G, Bailey D, et al. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci. 2010;107:8352\u20136.","journal-title":"Proc Natl Acad Sci"},{"key":"3637_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-63170-0","volume":"14","author":"C Demetriou","year":"2024","unstructured":"Demetriou C, Abid N, Butterworth M, Lezina L, Sandhu P, Howells L, et al. An optimised patient-derived explant platform for breast cancer reflects clinical responses to chemotherapy and antibody-directed therapy. Sci Rep. 2024;14:12833.","journal-title":"Sci Rep"},{"key":"3637_CR25","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1158\/2159-8290.CD-17-0833","volume":"8","author":"RW Jenkins","year":"2018","unstructured":"Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, et al. Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids. Cancer Discov. 2018;8:196\u2013215.","journal-title":"Cancer Discov"},{"key":"3637_CR26","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022;40:850\u201364.e859.","journal-title":"Cancer Cell"},{"key":"3637_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-97434-w","volume":"11","author":"MN Brodeur","year":"2021","unstructured":"Brodeur MN, Simeone K, Leclerc-Deslauniers K, Fleury H, Carmona E, Provencher DM, et al. Carboplatin response in preclinical models for ovarian cancer: comparison of 2D monolayers, spheroids, ex vivo tumors and in vivo models. Sci Rep. 2021;11:18183.","journal-title":"Sci Rep"},{"key":"3637_CR28","doi-asserted-by":"crossref","unstructured":"Mann B, Zhang X, Bell N, Adefolaju A, Thang M, Dasari R et al. A living ex vivo platform for functional, personalized brain cancer diagnosis. Cell Rep Med. 2023;101042:4.","DOI":"10.1016\/j.xcrm.2023.101042"},{"key":"3637_CR29","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/s42003-023-05531-5","volume":"6","author":"E Steinberg","year":"2023","unstructured":"Steinberg E, Friedman R, Goldstein Y, Friedman N, Beharier O, Demma JA, et al. A fully 3D-printed versatile tumor-on-a-chip allows multi-drug screening and correlation with clinical outcomes for personalized medicine. Commun Biol. 2023;6:1157.","journal-title":"Commun Biol"},{"key":"3637_CR30","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41416-019-0672-6","volume":"122","author":"IR Powley","year":"2020","unstructured":"Powley IR, Patel M, Miles G, Pringle H, Howells L, Thomas A, et al. Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery. Br J cancer. 2020;122:735\u201344.","journal-title":"Br J cancer"},{"key":"3637_CR31","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ccell.2022.03.004","volume":"40","author":"CG Hubert","year":"2022","unstructured":"Hubert CG, Rich JN. Patient-derived explants as tumor models. Cancer Cell. 2022;40:348\u201350.","journal-title":"Cancer Cell"},{"key":"3637_CR32","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1158\/1078-0432.CCR-22-0980","volume":"28","author":"J Weitz","year":"2022","unstructured":"Weitz J, Hurtado de Mendoza T, Tiriac H, Lee J, Sun S, Garg B, et al. An ex vivo organotypic culture platform for functional interrogation of human appendiceal cancer reveals a prominent and heterogenous immunological landscape. Clin Cancer Res. 2022;28:4793\u2013806.","journal-title":"Clin Cancer Res"},{"key":"3637_CR33","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1074\/mcp.RA118.000633","volume":"17","author":"EV Nguyen","year":"2018","unstructured":"Nguyen EV, Centenera MM, Moldovan M, Das R, Irani S, Vincent AD, et al. Identification of novel response and predictive biomarkers to Hsp90 inhibitors through proteomic profiling of patient-derived prostate tumor explants. Mol Cell Proteom. 2018;17:1470\u201386.","journal-title":"Mol Cell Proteom"},{"key":"3637_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1040665","volume":"13","author":"S Pettersen","year":"2023","unstructured":"Pettersen S, \u00d8y GF, Egeland EV, Juell S, Engebr\u00e5ten O, M\u00e6landsmo GM, et al. Breast cancer patient-derived explant cultures recapitulate in vivo drug responses. Front Oncol. 2023;13:1040665.","journal-title":"Front Oncol"},{"key":"3637_CR35","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s00423-023-03133-7","volume":"408","author":"M Mui","year":"2023","unstructured":"Mui M, Clark M, Vu TM, Clemons N, Hollande F, Roth S, et al. Use of patient-derived explants as a preclinical model for precision medicine in colorectal cancer: a scoping review. Langenbecks Arch Surg. 2023;408:392.","journal-title":"Langenbecks Arch Surg"},{"key":"3637_CR36","doi-asserted-by":"crossref","unstructured":"Nishida-Aoki N, Zhu S, Chan M, Kang Y, Fujita M, Jiang X et al. Drug screening in 3D microtumors reveals DDR1\/2-MAPK12-GLI1 as a vulnerability in cancer-associated fibroblasts. Cell Rep Med. 2025;6:102357.","DOI":"10.1016\/j.xcrm.2025.102357"},{"key":"3637_CR37","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.5858\/arpa.2023-0483-CP","volume":"148","author":"JD Goldsmith","year":"2024","unstructured":"Goldsmith JD, Troxell ML, Roy-Chowdhuri S, Colasacco CF, Edgerton ME, Fitzgibbons PL, et al. Principles of analytic validation of immunohistochemical assays: guideline update. Arch Pathol Lab Med. 2024;148:e111\u2013e153.","journal-title":"Arch Pathol Lab Med"},{"key":"3637_CR38","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2022111307","volume":"41","author":"NY Souren","year":"2022","unstructured":"Souren NY, Fusenig NE, Heck S, Dirks WG, Capes-Davis A, Bianchini F, et al. Cell line authentication: a necessity for reproducible biomedical research. EMBO J. 2022;41:e111307.","journal-title":"EMBO J"},{"key":"3637_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adq6830","volume":"10","author":"B Alsaed","year":"2024","unstructured":"Alsaed B, Smolander J, Laitinen H, Lin L, Bobik N, Lahtinen L, et al. Ex vivo modeling of precision immuno-oncology responses in lung cancer. Sci Adv. 2024;10:eadq6830.","journal-title":"Sci Adv"},{"key":"3637_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adn5875","volume":"10","author":"TN Nguyen","year":"2024","unstructured":"Nguyen TN, Horowitz LF, Krilov T, Lockhart E, Kenerson HL, Gujral TS, et al. Label-free, real-time monitoring of cytochrome C drug responses in microdissected tumor biopsies with a multi-well aptasensor platform. Sci Adv. 2024;10:eadn5875.","journal-title":"Sci Adv"},{"key":"3637_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60369-1","volume":"16","author":"V Subbiah","year":"2025","unstructured":"Subbiah V. Tissue-agnostic cancer therapies: promise, reality, and the path forward. Nat Commun. 2025;16:4972.","journal-title":"Nat Commun"},{"key":"3637_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103888","volume":"181","author":"V Debien","year":"2023","unstructured":"Debien V, Vignot S, Massard C, Malouf G, Hollebecque A, Scoazec J-Y, et al. Molecular analysis for refractory rare cancers: sequencing battle continues\u2013learnings for the MOSCATO-01 study. Crit Rev Oncol Hematol. 2023;181:103888.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3637_CR43","doi-asserted-by":"crossref","unstructured":"Zushin P-JH, Mukherjee S, Wu JC. FDA Modernization Act 2.0: transitioning beyond animal models with human cells, organoids, and AI\/ML-based approaches. J Clin Invest. 2023;133:e175824.","DOI":"10.1172\/JCI175824"},{"key":"3637_CR44","doi-asserted-by":"crossref","unstructured":"Beilmann M, Adkins K, Boonen HC, Hewitt P, Hu W, Mader R et al. Application of new approach methodologies for nonclinical safety assessment of drug candidates. Nat Rev Drug Discov. 2025;24:705\u201325.","DOI":"10.1038\/s41573-025-01182-9"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03637-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03637-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03637-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T23:03:14Z","timestamp":1764630194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03637-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":44,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2025,12,23]]}},"alternative-id":["3637"],"URL":"https:\/\/doi.org\/10.1038\/s41388-025-03637-0","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}